Atlas Four · Vaccine Atlas · Platform 05 — Live-Attenuated

Varivax

Live-attenuated VZV Oka strain varicella vaccine. Two-dose schedule (12-15 months + 4-6 years) achieves >95% seroconversion; 97-100% protection against severe varicella. Contraindicated in immunocompromised patients and pregnancy.

05 — Live-AttenuatedPlatform
subcutaneousRoute
Frozen storage at -15°C or colder during shipping; 2–8°C for up to 72 hours post-thaw; use immediately once reconstituted; discard if not used within 30 minutesCold Chain
activeStatus
This is an auto-generated stub page built from atlas entry frontmatter. A richer hand-crafted page is planned. See the atlas source for the full entry including detailed body sections.
varivax

Varivax

Live-attenuated VZV Oka strain varicella vaccine. Two-dose schedule (12-15 months + 4-6 years) achieves >95% seroconversion; 97-100% protection against severe varicella. Contraindicated in immunocompromised patients and pregnancy.

Entry Metadata

FieldValue
IDvarivax
NameVarivax
Statusactive
Last reviewed2026-06-06
Platform05 — Live-Attenuated
Delivery systemlyophilized live attenuated virus; reconstituted with sterile water
AdjuvantsNone
Routesubcutaneous
Dose schedule2-dose series: dose 1 at 12-15 months; dose 2 at 4-6 years (minimum interval 3 months). Previously 1-dose schedule 1995-2006.
ManufacturerMerck Sharp & Dohme (Merck)
Cold chainFrozen storage at -15°C or colder during shipping; 2–8°C for up to 72 hours post-thaw; use immediately once reconstituted; discard if not used within 30 minutes

Cross-Atlas Connections

immunizes-againstVaricella Zoster Virus connects-toImmune System connects-toImmunoglobulin G elicitsT Cytotoxic Cell elicitsB Cell prevents-damage-toPeripheral Nerve

Sources